Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

96.91 -1.25 (-1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
58 59 Next >
Better Buy: Pfizer vs. Gilead
Pfizer and Gilead look cheap right now. 
Via The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,400 Today
Via Benzinga
6 Best Healthcare Stocks to Buy Right Now
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat. 
Via MarketBeat
Topics Economy Intellectual Property
Exposures Economy Intellectual Property Product Safety
3 Cash-Rich Biotech Stocks to Bet on for the Long Haul
Cash rich biotech stocks can survive while most of their peers struggle with rising interest rates. Here are three to watch. 
Via InvestorPlace
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
Expert Ratings for Gilead Sciences
Via Benzinga
Could Gilead Sciences Stock Help You Become a Millionaire?
The company's dominant HIV therapies and growing oncology pipeline are delivering. 
Via The Motley Fool
P/E Ratio Insights for Gilead Sciences
Via Benzinga
A Look Into Gilead Sciences' Debt
Via Benzinga
2 Excellent Dividend Stocks to Buy for Less Than $100
Both companies are steals at current levels. 
Via The Motley Fool
Berkshire Hathaway, Gilead Sciences, Vertex Pharmaceuticals And A Break-Out Casino Stock Feature On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc. 
Via Benzinga
Strong Quant Screens Say These 7 Growth Stocks Are a Buy
StockRover’s quant screen is a grading system that brings up rewarding growth stocks to buy for income investors. 
Via InvestorPlace
Gamida Cell Stock Jumps Over 100% on FDA Approval
Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight bloo 
Via MarketBeat
Exposures Product Safety
6 Reasons to Buy Gilead Sciences Stock
The healthcare stock could be a solid pillar to build your portfolio around. 
Via The Motley Fool
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
From Gilead Sciences, Inc.
Via Business Wire
3 Dividend Stocks to Buy and Hold for the Next Decade
Long-term investors looking for income should especially like these stocks. 
Via The Motley Fool
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
From Gilead Sciences, Inc.
Via Business Wire
Dividend Income Update March 2023
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have Today
Would you have been better off investing in the S&P 500? 
Via The Motley Fool
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
3 Dividend Stocks Billionaires Seem to Love
It sometimes pays to follow the lead of successful people. 
Via The Motley Fool
Balm of Gilead’s Manuka Honey Skin Healing Cream Named “Best for Healing Skin Conditions” by US Weekly Magazine
Via Get News
Post-Pandemic Potential: Analysts Eye InflaRx COVID-19 Antibody For Market Breakthrough
Via Benzinga
GILD - Chart Of The Week
The daily chart looks pretty strong right now. The stock is trying to break through the resistance line that started around the beginning of December. 
Via Talk Markets
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis
A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),... 
Via Benzinga
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many... 
Via Benzinga
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
Key Takeaways: ImmuneOnco’s main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the... 
Via Benzinga
Is It Time to Buy These Ultra-Cheap Dividend Stocks?
These two biopharma stocks aren't exciting growth plays, but they are reliable income vehicles. 
Via The Motley Fool
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.